hotspot -WSS

hotspot

author：fashion 2025-09-27 19:37:46 - browse：15544

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： In Spain, a hospital brews its own CAR

hotspot

WSS

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Bristol Myers buys into radiopharmaceuticals with RayzeBio

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Menendez indictment could see pharma lose a key ally

Albert Bourla of Pfizer: worst biopharma CEO of 2023

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

How to save PrEP access — and even expand it

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: The latest on Moderna, Apellis, and Merck

The cancer drug shortage isn’t new — and neither are the solutions

Address the ethical violations that led to 'Three Identical Strangers'

Jerome Adams on the need for new antivirals for Covid

FDA advisers vote against ALS treatment from BrainStorm

Malaria cases in Florida and Texas: Here’s what you need to know

Kaiser Permanente unions announce official strike date

Wikipedia

Can sheer will power keep patients alive in their dying hours?

Menendez indictment could see pharma lose a key ally

Data show record exodus of life scientists from academia

In Spain, a hospital brews its own CAR

Grail spinoff by Illumina should end disastrous merger attempt

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Wikipedia

hotspot

knowledge

hotspot